RESEARCH ARTICLE   **Open Access**

Design, synthesis and evaluation of novel 3,5-disubstituted benzamide derivatives as allosteric glucokinase activators

Ajmer Singh Grewal[1,2], Rajeev Kharb[3], Deo Nandan Prasad[4], Jagdeep Singh Dua[4] and Viney Lather[3,5*]

Abstract

Glucokinase (GK) is the key enzyme expressed in β-cells of pancreas and liver hepatocytes and helps in the maintenance of blood glucose levels in normal range. Activators of GK are the novel category of drug candidates which activate GK enzyme allosterically and show their antidiabetic activity. A new series of 3,5-disubstituted benzamide analogues was designed, synthesized and evaluated as GK activators by in vitro assay as well as in silico docking studies followed by evaluation of antihyperglycemic activity in animal model. Amongst the synthesized derivatives, compounds **5c**, **5f**, **5i**, **6c**, **6e** and **6h** displayed excellent in vitro GK activation. Compounds **6c** and **6e** exhibited highest antihyperglycemic activity in oral glucose tolerance test in animal model. Compound **6e** displayed most significant antihyperglycemic activity and comparable to that of standard drug in animal studies. In addition, antihyperglycemic activity of the synthesized molecules was further supported by the in silico docking studies of the synthesized derivatives in the allosteric site of GK protein.

Keywords: Antidiabetic activity, Benzamides, Glucokinase, GK activators, In silico, In vitro assay, OGTT

Introduction

Diabetes mellitus, often simply known as diabetes is a long-lasting disorder of food metabolism characterized by hyperglycemia due to defect in insulin secretion, insulin function or together resulting in vascular and tissue damage leading to a variety of complications of diabetes related to kidney, eyes and nerves [1–5]. Type 2 diabetes (T2D) affects more than 90% of all the diabetic patients, and is a long-term malady of food metabolism bring about due to declined insulin function [6, 7]. Despite the fact that various types of oral hypoglycaemic drugs are existing intended for the T2D management, in majority of T2D patients no single drug is helpful in achieving long-term management of blood glucose under normal physiological range. Owing to the above reason, currently physicians prescribe combination of antidiabetic drugs at an early stage for the therapeutics of T2D. Moreover,

overdose of antihyperglycemic agents may lead to severe hypoglycaemia resulting in brutal toxic and side effects, and patients usually need urgent therapeutic treatment [7]. The medicinal chemists are currently working on discovering new potent antidiabetic medicines having pharmacologically different mechanism of action which can be used for single drug therapy of T2D with better safety profile. Results from numerous latest reports, including promising clinical information, have indicated that small-molecule allosteric glucokinase (GK) activators can be used to acquire these aims [8–10]. GK accelerates the breakdown of glucose to glucose-6-phosphate in presence of adenosine triphosphate (ATP) in cytoplasm and helps in the maintenance of the normal blood glucose levels in humans. GK enzyme is expressed primarily in β-cells of the pancreas and liver hepatocyte [9–11]. GK controls glucose-stimulated insulin secretion in β-cells of pancreas and metabolism of sugars in liver hepatocyte cells. GK is a promising target for the therapeutic management of T2D patients as it plays a major function in the regulation of carbohydrate breakdown. GK activators

*Correspondence: vinnylather@gmail.com
[3] Amity Institute of Pharmacy, Amity University, Noida, U.P 201303, India
Full list of author information is available at the end of the article

Grewal *et al. BMC Chemistry*   (2019) 13:2

Page 2 of 14

are the novel class of therapeutic agents which activate GK enzyme and show their hypoglycemic activity [8, 12–14]. A wide variety of small molecule derivatives including benzamide analogues [15–29], carboxamide derivatives [30–35], acrylamide derivatives [36], benzimidazole analogues [37, 38], quinazolines derivatives [39], thiazole derivatives [40], pyrimidine derivatives [41], and urea derivatives [42, 43] were developed in last decade to act as effective allosteric GK activators with potential antidiabetic effects. Several GK activators had been advanced to phase II clinical trials including Piragliatin, AZD6370, AZD1656, MK-0941, and AMG151; potent glucose lowering efficacy had been reported, and potential burdens have also been observed, including hypoglycaemia and increased triglyceride levels [11]. Various types of benzamide derivatives were reported as potent GK activators and the maximum drug discovery and development programmes linked to benzamide GK activators were primarily focused on the 3,5-disubstituted benzamide derivatives [16, 20–26, 44–51] possibly due to their orientation in the allosteric site and complementary binding pattern with the allosteric site amino acid residues of GK protein. In view of the significant contribution of the GK activators in the management of various diabetic disorders and the potential of 3,5-disubstituted benzamides as allosteric GK activators, we had made an attempt to design and synthesize some novel GK activators based on 3,5-disubstituted benzamide scaffold. The substitutions on benzamide nucleus were carried out in such a way that appreciable H-bond and hydrophobic interactions of the designed molecules with the amino acid residues in the allosteric site of GK protein can be achieved based on pharmacophoric requirements for binding of the ligands with GK protein (Fig. 1).

Materials and methods

All the chemicals, reagents, solvents and proteins required during research work were procured from SRL Pvt. Ltd. (Thane), Spectrochem Pvt. Ltd. (Thane), Sigma-Aldrich (Bangalore), Merck Pvt. Ltd. (Mumbai), S.D. Fine-Chem Ltd. (Mumbai), LOBA Chemie (Mumbai) and Fisher Scientific (Mumbai) etc., and used as such. Veego VMP-D melting point apparatus was used for melting point determination of synthesized derivatives. Thin layer chromatography (TLC) was used for monitoring the reaction completion using silica gel-G. Shimadzu IR affinity FTIR spectrophotometer (KBr pellet technique) was used for recording IR spectra. BrukerAvance II 300 MHz NMR spectrophotometer was used for recording [1]H Nuclear magnetic resonance (^{1}H-NMR) and ^{13}C-NMR spectra using DMSO-d_6 as solvent and presented in parts per million (δ, ppm) downfield from internal

Fig. 1 General structure of the newly designed 3,5-disubstituted benzamide GK activators and possible binding interaction with GK protein

standard (tetramethylsilane). Mass spectra were recorded on Waters Q-TOF Micromass spectrometer (ESI–MS).

Synthesis of sulfamoyl benzamide derivatives

Dry 3-nitrobenzoic acid (0.01 mol) was taken in a round bottom flask fixed with a magnetic stirrer and the temperature was kept constant between 10 and 15 °C using cold water bath. Chlorosulphonic acid (8.0 mL) was introduced cautiously and checked to substantiate no leakage. After acid had been dissolved and the exothermic reaction had been over, the reaction flask was heated on water bath at 70–80 °C for 2 h to complete the reaction followed by cooling the flask. The contents of flask were added to 150 g crushed ice with stirring to break the lumps and precipitates of 3-(chlorosulphonyl)-5-nitrobenzoic acid were filtered under vacuum followed by washing with cold water and air dried. The product obtained above (0.01 mol) was refluxed with commercially available amines (0.01 mol) in chloroform until reaction completion as monitored by TLC on silica gel G followed by cooling and precipitates of respective sulphonamides were dried. The various sulphonamides (0.01 mol) were refluxed with thionyl chloride (0.01 mol) for 3 h and excess $SOCl_2$ was distilled off to get the respective benzoyl chlorides. Benzoyl chloride (1 mmol) obtained above was refluxed with 2-aminopyrimidine (1.5 mmol) and 2-aminothiazole (1.5 mmol) in chloroform. The final product (benzamide derivatives) received after the evaporation of acetone was purified by recrystallization using ethyl alcohol [24, 26, 52].

3-Nitro-5-(phenylsulfamoyl)-N-(pyrimidin-2-yl)benzamide (5a)

Black solid; yield—56%; Mp (°C) 140–142; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.85 (s, 1H, NH, CO–NH), 8.04–8.46 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 6.95–8.45 (m, 3H, CH, C_4, C_5 and C_6 of pyrimidin-2-yl), 6.44–7.67

Grewal *et al. BMC Chemistry*   (2019) 13:2

Page 3 of 14

(m, 5H, C_2, C_3, C_4, C_5 and C_6 of C_6H_5), 2.33 (s, 1H, NH, SO_2NH); IR (KBr Pellets) ν cm^{-1}) 3328.21 (NH str., CO–NH), 3257.77 (NH str., SO_2–NH), 3012.81 (CH str., aromatic), 1670.35 (C=O str., CO–NH), 1624.06 (NH bend, Ar–NH), 1579.70 (C=N str.), 1533.48 (NO_2 sym. str.), 1483.26 (C=C str., aromatic), 1409.96 (NO_2 asym. str.), 1352.10 (SO_2 asym. str., SO_2–NH), 1141.86 (SO_2 sym. str., SO_2–NH), 717.52 (CH bend, aromatic).

3-[(2-Chlorophenyl)sulfamoyl]-5-nitro-N-(pyrimidin-2-yl) benzamide (5b)

Reddish brown solid; yield—63%; Mp (°C) 157–158; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.69 (s, 1H, NH, CO–NH), 8.21–8.60 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 6.95–8.45 (m, 3H, CH, C_4, C_5 and C_6 of pyrimidin-2-yl), 6.57–7.40 (m, 4H, C_3, C_4, C_5 and C_6 of C_6H_4Cl), 2.50 (s, 1H, NH, SO_2NH); ^{13}C-NMR (δ ppm, DMSO-d_6): 165.94 (C=O), 157.57 (C), 156.61 (CH), 148.34 (C), 135.83 (C), 132.93 (CH), 128.32 (C), 127.78 (CH), 124.13 (CH), 110.31 (CH); IR (KBr pellets) ν cm^{-1}: 3328.21 (NH str., CO–NH), 3257.77 (NH str., SO_2–NH), 3012.81 (CH str., aromatic), 1708.93 (C=N str.), 1674.21 (C=O str., CO–NH), 1614.42 (NH bend, Ar–NH), 1529.55 (NO_2 sym. str.), 1409.96 (NO_2 asym. str.), 1350.17 (SO_2 asym. str., SO_2–NH), 1236.37 (SO_2 sym. str., SO_2–NH); MS (ESI TOF) m/z for $C_{17}H_{12}ClN_5O_5S$ [M+H]$^+$ Calcd 434.032, found 434.087.

3-[(3-Chlorophenyl)sulfamoyl]-5-nitro-N-(pyrimidin-2-yl) benzamide (5c)

Reddish brown solid; yield—62%; Mp (°C) 161–162; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.61 (s, 1H, NH, CO–NH), 8.12–8.45 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 6.88–8.02 (m, 3H, CH, C_4, C_5 and C_6 of pyrimidin-2-yl), 6.23–7.17 (m, 4H, C_2, C_4, C_5 and C_6 of C_6H_4Cl), 2.54 (s, 1H, NH, SO_2NH); IR (KBr pellets) ν cm^{-1}: 3360.00 (NH str., CO–NH), 3331.07 (NH str., SO_2–NH), 3086.11 (CH str., aromatic), 1703.14 (C=N str.), 1674.21 (C=O str., CO–NH), 1614.42 (NH bend, Ar–NH), 1529.55 (NO_2 sym. str.), 1448.54 (NO_2 asym. str.), 1352.10 (SO_2 asym. str., SO_2–NH), 1149.57 (SO_2 sym. str., SO_2–NH), 785.03 (C–Cl str., aromatic), 713.66 (CH bend, aromatic).

3-[(4-Chlorophenyl)sulfamoyl]-5-nitro-N-(pyrimidin-2-yl) benzamide (5d)

Light brown solid; yield—61%; Mp (°C) 165–167; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.74 (s, 1H, NH, CO–NH), 8.18–8.62 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 6.92–8.46 (m, 3H, CH, C_4, C_5 and C_6 of pyrimidin-2-yl), 6.52–7.44 (m, 4H, C_2, C_3, C_5 and C_6 of C_6H_4Cl), 2.50 (s, 1H, NH, SO_2NH); IR (KBr pellets) ν cm^{-1}: 3363.86 (NH str., CO–NH), 3182.55 (NH str., SO_2–NH), 3086.11 (CH str.,

Aromatic), 1697.36 (C=N str.), 1674.21 (C=O str., CO–NH), 1616.35 (NH bend, Ar–NH), 1531.48 (NO_2 sym. str.), 1354.03 (NO_2 asym. str.), 1311.59 (SO_2 asym. str., SO_2–NH), 1143.79 (SO_2 sym. str., SO_2–NH).

3-Nitro-5-[(2-nitrophenyl)sulfamoyl]-N-(pyrimidin-2-yl) benzamide (5e)

Yellow solid; yield—68%; Mp (°C) 155–156; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.72 (s, 1H, NH, CO–NH), 8.14–8.56 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 6.78–8.34 (m, 3H, CH, C_4, C_5 and C_6 of pyrimidin-2-yl), 6.34–7.44 (m, 4H, C_3, C_4, C_5 and C_6 of $C_6H_4NO_2$), 2.54 (s, 1H, NH, SO_2NH); IR (KBr pellets) ν cm^{-1}: 3317.57 (NH str., CO–NH), 3157.46 (NH str., SO_2–NH), 3091.89 (CH str., aromatic), 1674.21 (C=O str., CO–NH), 1674.21 (C=N str.), 1620.21 (NH bend, Ar–NH), 1525.69 (NO_2 sym. str.), 1483.26 (C=C str., Aromatic), 1440–83 (NO_2 asym. str.), 1311.59 (SO_2 asym. str., SO_2-NH), 1157.29 (SO_2 sym. str., SO_2–NH), 713.66 (CH bend, aromatic).

3-Nitro-5-[(3-nitrophenyl)sulfamoyl]-N-(pyrimidin-2-yl) benzamide (5f)

Pale yellow solid; yield—65%; Mp (°C) 158–160; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.68 (s, 1H, NH, CO–NH), 8.26–8.56 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 6.82–8.42 (m, 3H, CH, C_4, C_5 and C_6 of pyrimidin-2-yl), 6.72–7.42 (m, 4H, C_2, C_4, C_5 and C_6 of $C_6H_4NO_2$), 2.53 (s, 1H, NH, SO_2NH); ^{13}C-NMR (δ ppm, DMSO-d_6): 166.42 (C=O), 136.06 (C), 157.92 (C), 157.42 (CH), 148.62 (C), 148.12 (C), 136.18 (C), 130.86 (CH), 127.02 (CH), 124.74 (CH), 111.12 (CH), 110.39 (CH), 108.19 (CH); IR (KBr pellets) ν cm^{-1}: 3358.07 (NH str., CO–NH), 3180.62 (NH str., SO_2–NH), 3093.82 (CH str., aromatic), 1674.21 (C=O str., CO–NH), 1624.06 (NH bend, Ar–NH), 1531.48 (NO_2 sym. str.), 1448.54 (NO_2 asym. str.), 1352.10 (SO_2 asym. str., SO_2–NH), 1153.43 (SO_2 sym. str., SO_2–NH), 719.45 (CH bend, aromatic); MS (ESI TOF) m/z for $C_{17}H_{12}N_6O_7S$ [M+H]$^+$ Calcd 445.056, found 445.016.

3-Nitro-5-[(4-nitrophenyl)sulfamoyl]-N-(pyrimidin-2-yl) benzamide (5g)

Yellow solid; yield—74%; Mp (°C) 152–154; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.98 (s, 1H, NH, CO–NH), 8.26–8.68 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 7.04–8.33 (m, 3H, CH, C_4, C_5 and C_6 of pyrimidin-2-yl), 6.45–7.34 (m, 4H, C_2, C_3, C_5 and C_6 of $C_6H_4NO_2$), 2.52 (s, 1H, NH, SO_2NH); IR (KBr pellets) ν cm^{-1}: 3471.87 (NH str., CO–NH), 3360.00 (NH str., SO_2–NH), 3089.96 (CH str., aromatic), 1674.21 (C=O str., CO–NH), 1624.06 (NH bend, Ar–NH), 1612.49 (C=N str.), 1531.48 (NO_2 sym. str.), 1479.40 (C=C str., aromatic), 1352.10 (NO_2 asym. str.),

Grewal *et al. BMC Chemistry*　　(2019) 13:2

Page 4 of 14

1311.59 (SO_2 asym. str., SO_2-NH), 1151.50 (SO_2 sym. str., SO_2–NH), 711.73 (CH bend, aromatic).

3-(Benzylsulfamoyl)-5-nitro-N-(pyrimidin-2-yl)benzamide (5h)

Light brown solid; yield—76%; Mp (°C) 138–140; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.63 (s, 1H, NH, CO–NH), 8.01–8.31 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 6.88–8.34 (m, 3H, CH, C_4, C_5 and C_6 of pyrimidin-2-yl), 6.51–7.42 (m, 5H, C_2, C_3, C_4, C_5 and C_6 of C_6H_5), 4.34 (s, 2H, CH of CH_2), 2.56 (s, 1H, NH, SO_2NH); FTIR (KBr pellets) ν cm^{-1}: 3377.36 (NH str., CO–NH), 3307.92 (NH str., SO_2–NH), 3024.38 (CH str., aromatic), 2926.01 (CH str., alkyl), 1712.43 (C=O str., CO–NH), 1624.06 (NH bend, Ar–NH), 1523.71 (NO_2 sym. str.), 1471.69 (NO_2 asym. str.), 1350.17 (SO_2 asym. str., SO_2–NH), 1122.57 (SO_2 sym. str., SO_2–NH), 709.80 (CH bend, aromatic).

3-(Ethylsulfamoyl)-5-nitro-N-(pyrimidin-2-yl)benzamide (5i)

White solid; yield—69%; Mp (°C) 147–148; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.68 (s, 1H, NH, CO–NH), 8.22–8.44 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 6.51–7.82 (m, 3H, CH, C_4, C_5 and C_6 of pyrimidin-2-yl), 7.62 (s, 1H, NH, SO_2NH), 2.48 (s, 3H, CH, CH_3), 1.12 (t, 3H, CH of CH_3); ^{13}C-NMR (δ ppm, DMSO-d_6): 169.92 (C=O), 165.10 (C), 164.95 (CH), 148.12 (C), 136.76 (C), 135.32 (C), 126.92 (CH), 124.72 (CH), 108.12 (CH), 40.01 (CH_2); IR (KBr pellets) ν cm^{-1}: 3381.21 (NH str., CO–NH), 3311.78 (NH str., SO_2–NH), 3086.11 (CH str., Aromatic), 2924.09 (CH str., alkyl), 1660.71 (C=O str., CO–NH), 1606.70 (NH bend, Ar–NH), 1529.55 (NO_2 sym. str.), 1400 (C=C str., aromatic), 1477.47 (NO_2 asym. str.), 1352.10 (SO_2 asym. str., SO_2–NH), 1141.86 (SO_2 sym. str., SO_2–NH), 713.66 (CH bend, aromatic); MS (ESI TOF) m/z for $C_{13}H_{13}N_5O_5S$ [M+H]$^+$ Calcd 352.071, found 353.024.

3-Nitro-5-(phenylsulfamoyl)-N-(1,3-thiazol-2-yl)benzamide (6a)

Dark brown solid; yield—76%; Mp (°C) 154–160; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.68 (s, 1H, NH, CO–NH), 8.24–8.48 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 7.56 (d, 1H, CH, C_5 of thiazol-2-yl), 7.34 (d, 1H, CH, C_4 of thiazol-2-yl), 6.68–7.34 (m, 5H, CH of C_6H_5), 2.54 (s, 1H, NH, SO_2NH); IR (KBr pellets) ν cm^{-1}: 3371.57 (NH str., CO–NH), 3311.78 (NH str., SO_2–NH), 3089.96 (CH str., Aromatic), 1724.43 (C=O str., CO–NH), 1624.06 (NH bend, Ar–NH), 1531.48 (NO_2 sym. str.), 1392.61 (NO_2 asym. str.), 1350.17 (SO_2 asym. str., SO_2-NH), 1143.79 (SO_2 sym. str., SO_2–NH), 715.81 (CH bend, aromatic), 653.87 (C–S str., aromatic).

3-[(2-Chlorophenyl)sulfamoyl]-5-nitro-N-(1,3-thiazol-2-yl) benzamide (6b)

White solid; yield—66%; Mp (°C) 181–182; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.72 (s, 1H, NH, CO–NH), 8.18–8.45 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 6.91–8.32 (m, 3H, CH, C_4, C_5 and C_6 of pyrimidin-2-yl), 6.35–7.24 (m, 4H, C_3, C_4, C_5 and C_6 of C_6H_4Cl), 2.52 (s, 1H, NH, SO_2NH); IR (KBr pellets) ν cm^{-1}: 3371.57 (NH str., CO–NH), 3311.78 (NH str., SO_2–NH), 3089.96 (CH str., aromatic), 1720.50 (C=O str., CO–NH), 1701.22 (C=N str.), 1631.78 (NH bend, Ar–NH), 1523.76 (NO_2 sym. str.), 1473.62 (NO_2 asym. str.), 1350.17 (SO_2 asym. str., SO_2–NH), 1143.79 (SO_2 sym. str., SO_2–NH), 790.81 (C–Cl str.), 713.66 (CH bend, aromatic), 655.80 (C–S str., aromatic).

3-[(3-Chlorophenyl)sulfamoyl]-5-nitro-N-(1,3-thiazol-2-yl) benzamide (6c)

Greenish solid; yield—59%; Mp (°C) 189–191; ^{1}H-NMR (δ ppm, DMSO-d_6): 9.22 (s, 1H, NH, CO–NH), 8.32–8.64 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 7.58 (d, 1H, CH, C_5 of thiazol-2-yl), 7.38 (d, 1H, CH, C_4 of thiazol-2-yl), 6.56–7.10 (m, 4H, CH of C_2, C_4, C_5 and C_6 of C_6H_4Cl), 2.51 (s, 1H, NH, SO_2NH); ^{13}C-NMR (δ ppm, DMSO-d_6): 170.02 (C=O), 165.18 (C), 148.22 (C), 136.42 (C), 135.04 (C), 134.72 (C), 132.92 (CH), 130.12 (CH), 126.03 (CH), 125.95 (CH), 124.42 (CH), 118.72 (CH), 117.18 (CH), 109.12 (CH); IR (KBr pellets) ν cm^{-1}: 3354.21 (NH str., CO–NH), 3284.77 (NH str., SO_2–NH), 3091.89 (CH str., aromatic), 1720.50 (C=O str., CO–NH), 1631.78 (NH bend, Ar–NH), 1531.48 (NO_2 sym. str.), 1442.75 (NO_2 asym. str.), 1350.17 (SO_2 asym. str., SO_2–NH), 1143.79 (SO_2 sym. str., SO_2–NH), 786.96 (C–Cl str.), 717.52 (CH bend, aromatic), 651.94 (C–S str., aromatic), MS (ESI TOF) m/z for $C_{16}H_{11}ClN_4O_5S_2$ [M+H]$^+$ Calcd 438.993, found 439.012.

3-[(4-Chlorophenyl)sulfamoyl]-5-nitro-N-(1,3-thiazol-2-yl) benzamide (6d)

Dark brown solid; yield—77%; Mp (°C) 185–186; ^{1}H-NMR (δ ppm, DMSO-d_6): 8.66 (s, 1H, NH, CO–NH), 8.16–8.48 (s, 3H, CH, C_2, C_4 and C_6 of C_6H_3CO), 6.90–8.40 (m, 3H, CH, C_4, C_5 and C_6 of pyrimidin-2-yl), 6.46–7.28 (m, 4H, C_2, C_3, C_5 and C_6 of C_6H_4Cl), 2.46 (s, 1H, NH, SO_2NH); IR (KBr pellets) ν cm^{-1}: 3354.21 (NH str., CO–NH), 3284.77 (NH str., SO_2–NH), 3091.89 (CH str., aromatic), 1726.29 (C=O str., CO–NH), 1658.78 (NH bend, Ar–NH), 1608.63 (C=N str.), 1529.55 (NO_2 sym. str.), 1442.75 (NO_2 asym. str.), 1352.10 (SO_2 asym. str., SO_2–NH), 1141.86 (SO_2 sym. str., SO_2–NH), 790.81 (C–Cl str.), 713.66 (CH bend, aromatic), 650.01 (C–S str., aromatic).

Grewal et al. BMC Chemistry   (2019) 13:2

Page 5 of 14

3-Nitro-5-[(2-nitrophenyl)sulfamoyl]-N-(1,3-thiazol-2-yl) benzamide (6e)

Yellowish brown solid; yield—72%; Mp (°C) 180–182; ^{1}H-NMR (δ ppm, DMSO-d$_6$): 8.98 (s, 1H, NH, CO–NH), 8.34–8.76 (s, 3H, CH, C$_2$, C$_4$ and C$_6$ of C$_6$H$_3$CO), 7.56 (d, 1H, CH, C$_5$ of thiazol-2-yl), 7.28 (d, 1H, CH, C$_4$ of thiazol-2-yl), 6.68–8.10 (m, 4H, CH of C$_3$, C$_4$, C$_5$ and C$_6$ of C$_6$H$_4$NO$_2$), 2.50 (s, 1H, NH, SO$_2$NH); ^{13}C-NMR (δ ppm, DMSO-d$_6$): 165.02 (C=O), 167.61 (C), 148.23 (C), 142.53 (C), 136.77 (C), 134.62 (C), 132.44 (CH), 128.90 (CH), 128.79 (CH), 119.42 (CH), 115.28 (CH), 107.78 (CH); IR (KBr Pellets) ν cm^{-1}: 3498.87 (NH str., CO–NH), 3385.07 (NH str., SO$_2$-NH), 3089.96 (CH str., aromatic), 1687.71 (C=O str., CO–NH), 1622.13 (NH bend, Ar–NH), 1608.63 (C=N str.), 1529.55 (NO$_2$ sym. str.), 1438.90 (NO$_2$ asym. str.), 1348.24 (SO$_2$ asym. str., SO$_2$–NH), 1145.72 (SO$_2$ sym. str., SO$_2$–NH), 713.66 (CH bend, aromatic), MS (ESI TOF) m/z for C$_{16}$H$_{11}$N$_5$O$_7$S$_2$ [M+H]$^+$ Calcd 450.017, found 450.283.

3-Nitro-5-[(3-nitrophenyl)sulfamoyl]-N-(1,3-thiazol-2-yl) benzamide (6f)

Dark yellow solid; yield—68%; Mp (°C) 176–177; ^{1}H-NMR (δ ppm, DMSO-d$_6$): 8.64 (s, 1H, NH, CO–NH), 8.18–8.56 (s, 3H, CH, C$_2$, C$_4$ and C$_6$ of C$_6$H$_3$CO), 6.92–8.48 (m, 3H, CH, C$_4$, C$_5$ and C$_6$ of pyrimidin-2-yl), 6.53–7.42 (m, 4H, C$_3$, C$_4$, C$_5$ and C$_6$ of C$_6$H$_4$NO$_2$), 2.53 (s, 1H, NH, SO$_2$NH); IR (KBr pellets) ν cm^{-1}: 3275.13 (NH str., CO–NH), 3091.89 (NH str., SO$_2$–NH), 2962.66 (CH str., aromatic), 1718.58 (C=O str., CO–NH), 1627.92 (NH bend, Ar–NH), 1529.55 (NO$_2$ sym. str.), 1444.68 (NO$_2$ asym. str.), 1350.17 (SO$_2$ asym. str., SO$_2$–NH), 1141.86 (SO$_2$ sym. str., SO$_2$–NH), 719.45 (CH bend, aromatic), 661.58 (C–S str., aromatic).

3-Nitro-5-[(4-nitrophenyl)sulfamoyl]-N-(1,3-thiazol-2-yl) benzamide (6g)

Reddish brown solid; yield—59%; Mp (°C) 182–183; ^{1}H-NMR (δ ppm, DMSO-d$_6$): 8.88 (s, 1H, NH, CO–NH), 8.54–8.78 (s, 3H, CH, C$_2$, C$_4$ and C$_6$ of C$_6$H$_3$CO), 7.51 (d, 1H, CH, C$_5$ of thiazol-2-yl), 7.22 (d, 1H, CH, C$_4$ of thiazol-2-yl), 6.92–8.06 (m, 4H, CH of C$_2$, C$_3$, C$_5$ and C$_6$ of C$_6$H$_4$NO$_2$), 2.58 (s, 1H, NH, SO$_2$NH); IR (KBr pellets) ν cm^{-1}: 3352.28 (NH str., CO–NH), 3238.48 (NH str., SO$_2$–NH), 3096.75 (CH str., aromatic), 1674.21 (C=O str., CO–NH), 1631.78 (NH bend, Ar–NH), 1531.48 (NO$_2$ sym. str.), 1438.90 (NO$_2$ asym. str.), 1348.24 (SO$_2$ asym. str., SO$_2$–NH), 1143.79 (SO$_2$ sym. str., SO$_2$–NH), 711.73 (CH bend, aromatic), 626.87 (C–S str., aromatic).

3-(Benzylsulfamoyl)-5-nitro-N-(1,3-thiazol-2-yl)benzamide (6h)

Orange solid; yield—53%; Mp (°C) 164–166; ^{1}H-NMR (δ ppm, DMSO-d$_6$): 9.89 (s, 1H, NH, CO–NH), 8.18–8.20 (s, 3H, CH, C$_2$, C$_4$ and C$_6$ of C$_6$H$_3$CO), 7.27 (d, 1H, CH, C$_5$ of thiazol-2-yl), 7.05 (d, 1H, CH, C$_4$ of thiazol-2-yl), 7.05–7.26 (m, 4H, CH of C$_2$, C$_3$, C$_4$, C$_5$ and C$_6$ of C$_6$H$_5$), 7.26 (s, 1H, NH, SO$_2$NH), 4.81 (s, 2H, CH of CH$_2$); ^{13}C-NMR (δ ppm, DMSO-d$_6$): 170.69 (C=O), 167.61 (C), 153.09 (C), 140.57 (C), 139.27 (C), 137.69 (C), 132.54 (CH), 128.95 (CH), 128.79 (CH), 115.28 (CH), 45.34 (CH$_2$); IR (KBr pellets) ν cm^{-1}: 3361.93 (NH str., CO–NH), 3186.40 (NH str., SO$_2$-NH), 3020.53 (CH str., aromatic), 2864.29 (CH str., alkyl), 1666.50 (C=O str., CO–NH), 1614.42 (NH bend, Ar–NH), 1531.48 (NO$_2$ sym. str.), 1473.48 (NO$_2$ asym. str.), 1352.10 (SO$_2$ asym. str., SO$_2$–NH), 1118.71 (SO$_2$ sym. str., SO$_2$–NH), 709.80 (CH bend, aromatic), 663.51 (C-S str., aromatic), MS (ESI TOF) m/z for C$_{17}$H$_{14}$N$_4$O$_5$S$_2$ [M+H]$^+$ Calcd 419.047, found 420.156.

3-(Ethylsulfamoyl)-5-nitro-N-(1,3-thiazol-2-yl)benzamide (6i)

Light brown solid; yield—48%; Mp (°C) 162–163; ^{1}H-NMR (δ ppm, DMSO-d$_6$): 8.58 (s, 1H, NH, CO–NH), 8.21–8.60 (s, 3H, CH, C$_2$, C$_4$ and C$_6$ of C$_6$H$_3$CO), 6.95–8.45 (m, 3H, CH, C$_4$, C$_5$ and C$_6$ of pyrimidin-2-yl), 7.52 (s, 1H, NH, SO$_2$NH), 2.58 (s, 3H, CH, CH$_3$), 1.35 (t, 3H, CH of CH$_3$); IR (KBr pellets) ν cm^{-1}: 3315.63 (NH str., CO–NH), 3205.69 (NH str., SO$_2$-NH), 3020.53 (CH str., aromatic), 2856.58 (CH str., Alkyl), 1674.21 (C=O str., CO–NH), 1662.64 (C=N str.), 1618.28 (NH bend, Ar–NH), 1521.84 (NO$_2$ sym. str.), 1483.26 (NO$_2$ asym. str.), 1350.17 (SO$_2$ asym. str., SO$_2$–NH), 1145.72 (SO$_2$ sym. str., SO$_2$–NH), 715.59 (CH bend, aromatic).

In vitro enzyme assay

The GK activity of the synthesized compounds was evaluated using a coupled reaction with glucose-6-phosphate dehydrogenase (G-6-PDH) spectrometrically [26, 53–55]. All the compounds were prepared in dimethyl sulfoxide (DMSO) and the assay was performed in a final volume of 2000 μL containing 2-(4-(2-hydroxyethyl) piperazin-1-yl)ethanesulfonic acid (25 mM, pH 7.4), glucose (10 mM), potassium chloride (25 mM), magnesium chloride (1 mM), dithiothreitol (1 mM), ATP (1 mM), NAD (1 mM), G-6-PDH (2.5 U/mL), GK (0.5 μg), and compounds under investigation (10 μM). Absorbance was measured at 340 nm after 3 min incubation period and GK activation fold by the synthesized compounds and GK fold activation was calculated compared to control (GK activation by the control (i.e., DMSO only) was considered as 100%).

Docking studies

Docking simulations were performed in the allosteric site of GK protein with Glide 5.8 module of Schrödinger Suite 2012 extra precision mode [56–58]. The X-ray crystallographic information of GK protein with the

Grewal *et al. BMC Chemistry*   (2019) 13:2

Page 6 of 14

allosteric activator was obtained from RCSB protein data bank. After studying a numbers of entries, the best entry (PDB code: 3IMX) was selected based on resolution and was used as the docking model. The 2D structures for the designed ligands were drawn in MarvinSketch and transformed to 3D with LigPrep 2.5 with OPLS2005 force field [59]. An analogous docking method was used for the molecular docking of the synthesized derivatives as described in detail in earlier publications using Glide and the ligand poses with most favorable docking score (Glide score and Glide energy) were selected [24, 25]. The binding interactions of the ligands with GK protein were analysed further for the docked poses of the ligands using PyMOL (the PyMOL molecular graphics system, Schrödinger, LLC).

Oral glucose tolerance test (OGTT)

Healthy Sprague–Dawley rats (150–200 g) procured from Lala Lajpat Rai University of Veterinary and Animal Sciences, Hisar and kept at controlled room temperature and fed with the normal pellet diet and water ad libitum, prior to the dietary manipulation. Consent was taken from Institutional Animal Ethics Committee to conduct this study (Approval No. JCDMCOP/IAEC/07/15/30). Based on the results of in vitro GK assay and docking studies, selected synthesized derivatives (**5b**, **5f**, **5i**, **6c**, **6e** and **6h**) were evaluated in rat OGTT model. Rats were divided into different groups containing six animals in each group and all the rats were fasted overnight for at least 8 h before experiment. Control group was administered vehicle only (5% DMSO, p.o.), standard group was administered metformin (30 mg/kg, p.o.), and test groups were administered compounds **5b**, **5f**, **5i**, **6c**, **6e** and **6h** (50 mg/kg, p.o.). All the animals were loaded with glucose (3 g/kg, p.o.) 30 min after drug administration. Blood samples were collected just prior to drug administration, and 0, 30, 60, 90 and 120 min after oral glucose administration. Blood glucose level was measured immediately and glucose area under curve (AUC) was calculated from the data (from 0 to 2 h). The OGTT assay results were statistically analyzed by two-way ANOVA [26, 27, 60].

Results and discussion
Chemistry

The synthetic pathway used for the preparation of 3,5-disubstituted benzamide derivatives is highlighted in Scheme 1. In brief, 3-(chlorosulphonyl)-5-nitrobenzoic acid (**2**) was prepared by chlorosulphonation of 3-nitrobenzoic acid (**1**) and the resultant product was reacted with amines to get the desired sulphonamide derivatives (**3**). The sulphonamides obtained above were reacted with $SOCl_2$ to get respective benzoyl chlorides (**4**) which were then reacted with available heteroaromatic amines to obtain the final products (**5a**–**5i** and **6a**–**6i**). The physiochemical properties of the synthesized compounds are presented in Table 1. The synthesis as well as purity of synthesized derivatives was ensured by single spot TLC and was further established by their consistent FTIR, ^{1}H and ^{13}C NMR, and mass spectra.

The ^{1}H-NMR spectra of the synthesized benzamide derivatives showed the singlet signal equivalent to one proton of CONH functional group at around δ 9–10 ppm

Scheme 1 Synthetic route followed for 3,5-disubstituted benzamide derivatives. Reagents and conditions: (a) chlorosulphonic acid, 80 °C, 2 h; (b) NH$_2$-R, chloroform, reflux; c thionyl chloride, chloroform, reflux; (d) 2-aminopyrimidine, chloroform, reflux; (e) 2-aminothiazole, chloroform, reflux

Grewal *et al. BMC Chemistry*   (2019) 13:2

Page 7 of 14

Table 1 Physicochemical properties and GK activity of the synthesized 3,5-disubstituted benzamide derivatives

Compound	R	Molecular Formula	M. Pt. (°C)	R_f^a	% Yield	GK activity[b]
5a	$-C_6H_5$	$C_{17}H_{13}N_5O_5S$	140–142	0.62	56	1.43 ± 0.06
5b	2-ClC_6H_4-	$C_{17}H_{12}ClN_5O_5S$	157–158	0.37	63	1.74 ± 0.08
5c	3-ClC_6H_4-	$C_{17}H_{12}ClN_5O_5S$	161–162	0.53	62	1.34 ± 0.05
5d	4-ClC_6H_4-	$C_{17}H_{12}ClN_5O_5S$	165–167	0.57	61	1.36 ± 0.03
5e	2-$NO_2C_6H_4-$	$C_{17}H_{12}N_6O_7S$	155–156	0.69	68	1.49 ± 0.07
5f	3-$NO_2C_6H_4-$	$C_{17}H_{12}N_6O_7S$	158–160	0.72	65	1.89 ± 0.06
5g	4-$NO_2C_6H_4-$	$C_{17}H_{12}N_6O_7S$	152–154	0.69	74	1.65 ± 0.04
5h	$-CH_2C_6H_5$	$C_{18}H_{15}N_5O_5S$	138–140	0.62	76	1.20 ± 0.06
5i	$-C_2H_5$	$C_{13}H_{13}N_5O_5S$	147–148	0.56	69	1.68 ± 0.04
6a	$-C_6H_5$	$C_{16}H_{12}N_4O_5S_2$	154–160	0.75	76	1.65 ± 0.06
6b	2-ClC_6H_4-	$C_{16}H_{11}ClN_4O_5S_2$	181–182	0.56	66	1.59 ± 0.08
6c	3-ClC_6H_4-	$C_{16}H_{11}ClN_4O_5S_2$	189–191	0.64	59	2.11 ± 0.05
6d	4-ClC_6H_4-	$C_{16}H_{11}ClN_4O_5S_2$	185–186	0.62	77	1.55 ± 0.08
6e	2-$NO_2C_6H_4-$	$C_{16}H_{11}N_5O_7S_2$	180–182	0.38	72	2.11 ± 0.09
6f	3-$NO_2C_6H_4-$	$C_{16}H_{11}N_5O_7S_2$	176–177	0.48	68	1.37 ± 0.07
6g	4-$NO_2C_6H_4-$	$C_{16}H_{11}N_5O_7S_2$	182–183	0.42	59	1.24 ± 0.08
6h	$-CH_2C_6H_5$	$C_{17}H_{14}N_4O_5S_2$	164–166	0.55	53	1.99 ± 0.07
6i	$-C_2H_5$	$C_{12}H_{12}N_4O_5S_2$	162–163	0.58	48	1.08 ± 0.09

[a] TLC mobile phase: Benzene: Ethyl acetate (7:3)

[b] All the values are mean of three measurements ± SD (as GK fold activation at 10 µM concentration compared to control i.e., DMSO only)

confirming the formation of amide linkage and presence of singlet signal for one NH proton of SO_2NH functional group at around δ 2.5 ppm confirmed the formation of sulphonamides in the synthesized benzamide derivatives. The presence of three singlet signals at around δ 8 ppm belonging to the protons at C_2, C_4 and C_6 of the phenyl ring derived from 3-nitrobenzoic acid (*meta*-nitro benzoic acid) confirmed that the amide bond, sulphonamide linkage and NO_2 group were placed *meta* to each other i.e., separated by C_2, C_4 and C_6. Due to this reason, the protons of C_2, C_4 and C_6 of the phenyl ring had shown singlet signals at such a high chemical shift value. In the ¹H-NMR spectra of compounds **5a–5i**, two doublet signals and one triplet signal corresponding to three aromatic CH protons were observed at around δ 8 ppm confirming the presence of pyrimidin-2-yl ring in the structure of these benzamide derivatives. In the ¹H-NMR spectra of compounds **6a–6i**, two doublet signals corresponding to two aromatic CH protons were observed at around δ 7–8 ppm which confirmed that 2-amino-4-thiazol was reacted with nitro benzoyl chloride derivatives for the synthesis of respective benzamide derivatives. In the ¹H-NMR spectra of compound **5i**, a multiplet signal for the alkyl protons in the range δ 2.5–4.0 ppm corresponding to methylene group ($-CH_2-$) and a doublet signal in the range δ 1.8–2.5 ppm corresponding to protons of the methyl group confirmed the presence of ethyl group attached to SO_2NH- in the structure

of these compounds. In ¹H-NMR spectrum of compound **35**, a doublet signal for the alkyl protons around δ 4.8 ppm and a multiplet signal around δ 6–8 ppm corresponding to five aromatic CH protons of the phenyl ring confirmed the presence of benzyl ring attached to SO_2NH- in the structure of these compounds. In the ¹H-NMR spectra of compound **6a**, two doublet signals and three triplet signals equivalent to five aromatic CH protons were observed at around δ 7 ppm which depicted that unsubstituted phenyl ring attached to SO_2NH was present in the structure of these compounds. In the ¹H-NMR spectra of compound **5b** two doublet signals and two triplet signals equivalent to four aromatic CH protons were observed in the range δ 7.1–7.6 ppm depicting the presence of 2-chlorophenyl ring attached to SO_2NH in the structure of these compounds. In the ¹H-NMR spectrum of compound **6c** one singlet signal, two doublet signals and one triplet signal equivalent to four aromatic CH protons were observed in the range δ 6.8–7.3 ppm indicating the presence of 3-chlorophenyl ring attached to SO_2NH. In the ¹H-NMR spectrum of compound **6e** two doublet signals and two triplet signals equivalent to four aromatic CH protons were observed in the range δ 6.6–8.1 ppm depicting the presence of 2-nitrophenyl ring attached to SO_2NH. In the ¹H-NMR spectrum of compound **5f** one singlet signal, two doublet signals and one triplet signal equivalent to four aromatic CH protons were observed indicating the presence of 3-nitrophenyl

Grewal *et al. BMC Chemistry*   (2019) 13:2

Page 8 of 14

ring attached to SO_2NH. In the ^1H-NMR spectrum of compound **6g**, four doublet signals corresponding to four aromatic CH protons were observed in the range δ 6.9–8.1 ppm indicating the presence of 4-nitrophenyl ring attached to SO_2NH. In the ^{13}C-NMR spectra of synthesized compounds, singlet signal equivalent to carbonyl (C=O) carbon was observed at around δ 165–170 ppm indicating the presence of amide linkage (i.e., CO–NH) in the structure of the synthesized benzamide derivatives. In the ^{13}C-NMR spectra of synthesized compounds, singlet signal for carbon at around δ 152 ppm confirming the presence of nitro group in the structure of synthesized compounds. In the ^{13}C-NMR spectra of compounds **5b**, **5f** and **5i**; three singlet signals at around δ 157 ppm corresponding to C_2, C_5 and C_6 of pyrimidine ring and one singlet signal at around δ 120 ppm were observed indicating the presence of pyrimidin-2-yl ring attached to CONH group in the structure of these compounds. A singlet signal at around δ 165 ppm corresponding to C_2, δ 132 ppm corresponding to C_4 and δ 109 ppm corresponding to C_5 in the ^{13}C-NMR spectra of compounds **6c**, **6e** and **6h** depicted the presence of thiazol-2-yl ring attached to CONH group in the structure of these benzamide derivatives. In the ^{13}C-NMR spectra of compound **5i** singlet signals corresponding to CH_2 and CH_3 at around δ 40 ppm and δ 14 ppm indicated the presence of ethyl group attached to SO_2NH group in the structure of compound **5i**. In the ^{13}C-NMR spectrum of compound **6h**, a singlet signal corresponding to CH_2 at around δ 45 ppm was observed indicating the presence methylene group (–CH_2–) attached to SO_2NH. The IR spectra of the synthesized benzamide derivatives showed the presence of amide NH-stretching vibrations at around 3300–3200 cm^{-1}; aromatic CH-stretching vibrations above 3000 cm^{-1}; SO_2 asymmetric and symmetric stretching vibrations at around 1400–1300 cm^{-1} and 1200–1100 cm^{-1} respectively; and sulphonamide NH-stretching vibrations in the range 3400–3100 cm^{-1}, thus supporting the fact that an amide linkage (CO–NH) and a sulphonamide functional group (SO_2–NH) were present in the structure of the synthesized molecules. In the IR spectra of the synthesized molecules, C=O stretching vibrations in the range 1700–1600 cm^{-1} indicated the presence of amide carbonyl functional group in the structure of the synthesized benzamide derivatives. The NH-bending vibrations at around 1600 cm^{-1} were present in the IR spectra of the synthesized molecules confirming the presence of aromatic NH-functional group in the structure of the synthesized molecules. In the IR spectra of the synthesized molecules, CH-bending vibrations at around 800–700 cm^{-1} confirmed the presence of aromatic ring in the structure of molecules. The IR spectra of the synthesized benzamide derivatives

showed the presence of NO_2 symmetric and asymmetric stretching vibrations around 1600–1500 cm^{-1} and 1400–1300 cm^{-1} respectively supporting the presence of nitro functional group in the structure of all the synthesized molecules. In the IR spectra of compounds **5a**–**5i**, presence of C=N stretching vibrations at around 1700–1600 cm^{-1} depicted the occurrence of pyrimidine ring in these compounds. The IR spectra of compounds, **5h**, **5i**, **6h** and **6i** showed aliphatic CH-stretching vibrations in the range 3000–2800 cm^{-1} confirming the presence of aliphatic group (e.g., ethyl or benzyl) in the structure of these compounds. The IR spectra of compounds 28–36 showed the asymmetric stretching vibrations at around 1650–1600 cm^{-1} and stretching vibrations around 700–600 cm^{-1} corresponding to aromatic C–S depicting the presence of thiazole ring in the structure of these compounds.

In vitro enzyme activity

The results of the in vitro GK assay (fold activation compared to control i.e., DMSO only) are presented in Table 1. Among the synthesized derivatives tested in vitro, compounds **5b**, **5f**, **5i**, **6c**, **6e** and **6h** showed maximum fold activation (in the range 1.7–2.1 compared to control) of GK enzyme. Compounds **5e**, **5g**, **6a**, **6b** and **6d** showed moderate fold activation (around than 1.5 compared to control) of GK enzyme. Compounds **5a**, **5c**, **5d**, **5h**, **6f** and **6g** demonstrated lower fold activation (around 1.25) of GK enzyme compared to that of control. Compound **6i** was found to be inactive in the in vitro GK assay. The results of in vitro GK assay depicted that introduction of the thiazol-2-yl ring attached to CONH resulted in increased GK activity (most potent) compared to compounds bearing pyrimidine-2-yl ring (compounds **6c** and **6e**). Amongst the compounds bearing pyrimidin-2-yl ring, the derivative bearing *N*-3-nitrophenyl sulphonamide group (compound **5f**) demonstrated highest GK fold activation of 1.89. The *N*-thiazol-2-yl substituted benzamide derivatives bearing *N*-3-chlorophenyl and *N*-2-nitrophenyl substituted sulphonamide group (compounds **6c** and **6e**) displayed highest GK fold activation of 2.11 compared to control. The results of in vitro GK assay demonstrated that replacement of the aromatic ring attached to sulphonamide NH with alkyl group such as ethyl (compound **6i**) led to reduced GK activity compared to the compounds bearing substituted aromatic ring attached to sulphonamide NH.

Molecular docking studies

Lead optimization of the synthesized derivatives was done via calculation of drug-likeness properties (log P, mol. wt., hydrogen bond acceptors (HBA), and hydrogen bond donors (HBD) and all the synthesized derivatives

Grewal *et al. BMC Chemistry* (2019) 13:2

Page 9 of 14

Table 2 Molecular properties, docking score and Glide energy of the synthesized 3,5-disubstituted benzamide molecules

| Compound	M. Wt.[a]	log P[a]	HBA[a]	HBD[a]	Glide score	Glide energy
5a	399.38	2.25	7	2	− 9.59	− 45.95
5b	433.82	2.85	7	2	− 11.26	− 53.63
5c	433.82	2.85	7	2	− 11.23	− 50.77
5d	433.82	2.85	7	2	− 9.97	− 43.86
5e	444.38	2.19	9	2	− 10.20	− 51.40
5f	444.38	2.19	9	2	− 10.37	− 57.62
5g	444.38	2.19	9	2	− 9.91	− 56.42
5h	413.41	2.31	7	2	− 10.69	− 56.89
5i	351.34	0.95	7	2	− 10.12	− 50.57
6a	404.42	2.84	6	2	− 11.22	− 48.59
6b	438.86	3.44	6	2	− 9.96	− 53.62
6c	438.86	3.44	6	2	− 10.98	− 53.01
6d	438.86	3.44	6	2	− 10.86	− 38.77
6e	449.41	2.78	8	2	− 10.35	− 56.93
6f	449.41	2.78	8	2	− 9.86	− 56.19
6g	449.41	2.78	8	2	− 10.31	− 56.48
6h	418.44	2.97	6	2	− 11.11	− 57.19
6i	356.37	1.54	6	2	− 9.62	− 47.28

[a] Mol. Wt., LogP, HBA, and HBD were calculated using MarvinSketch (Marvin 15.9.21, 2015, ChemAxon, Budapest, Hungary)

showed appreciable drug-like properties as ascertained using Lipinski's rule of 5 (Table 2). The docking studies were performed using Glide in the allosteric site of GK protein (PDB entry: 3IMX) and validated by docking of 3IMX ligand in the allosteric site. The designed GK activators were docked in the allosteric binding site comprising of Arg63, Tyr215, Met210, Tyr214, Val452 and Val455 residues. Glide score and Glide energy of the synthesized derivatives are presented in Table 2. All the synthesized 3,5-disubstituted benzamide derivatives showed significant binding in the allosteric site as determined by analysing the H-bond and hydrophobic interactions of the selected best docked poses. Based on their most favourable Glide score, lowest Glide energy (kcal/mol) and binding interactions with allosteric site residues of GK protein, compounds **5b**, **5f**, **5i**, **6c**, **6e** and **6h** were further analyzed in details using PyMOL to explore the binding mode and docking interactions of the designed molecules with the amino acid residues in the allosteric site of GK protein.

An overlay of docked poses of the selected compounds **5b**, **5f**, **5i**, **6c**, **6e** and **6h** with that of 3IMX ligand showed that these compounds had the similar orientation and binding pattern in the allosteric binding site of GK enzyme as that of co-crystallized ligand (Fig. 2). All the selected molecules were found to bind to an allosteric pocket of GK protein, which is about 20 Å remote from the glucose binding site [61]. The pyrimidin-2-yl group attached to benzamide nucleus of compounds **5b**, **5f** and

5i protruded in the hydrophobic pocket showing the interactions with Val455, Ala456, and Lys459 of the R13 helix, as well as Pro66 of connecting region I and Ile159 of the large domain, phenyl ring packs between Tyr214, Met210 and Val455 whereas the substituted aryl group of sulphonamide oriented into the hydrophobic pocket comprising residues Leu451, Val 455, Tyr215, and Trp99. The thiazol-2-yl group attached to benzamide nucleus of compounds **6c**, **6e** and **6h** protruded in the hydrophobic pocket showing the interactions with Val455, Ala456, and Lys459 of the R13 helix, as well as Pro66 of connecting region I and Ile159 of the large domain, the phenyl ring was found to pack between Tyr214, Met210 and Val455 whereas the substituted aryl group of sulphonamide oriented into the hydrophobic pocket comprising residues Leu451, Val 455, Tyr215, and Trp99.

Docked pose showing H-bond interactions of the selected compounds **5b**, **5f**, **5i**, **6c**, **6e** and **6h** in the allosteric binding site of GK protein is presented in Fig. 3. The selected 3,5-disubstituted benzamide displayed similar H-bonding interactions with amino acid residues in the allosteric binding site of GK protein as that of the co-crystallized ligand (PDB ID: 3IMX). The docked pose of compound **5b** showed the H-bond interaction between the '1-N' of pyrimidin-2-yl and benzamide NH with NH and backbone carbonyl of Arg63 residue on GK protein with H-bond distance of 2.8 Å and 3.0 Å respectively. Compound **5f** showed the H-bond interaction between the '1-N' of pyrimidin-2-yl and benzamide NH with NH

Fig. 2 Superimpose of the docked poses for compounds **5b**, **5f**, **5i**, **6c**, **6e** and **6h** (red sticks) with that of co-crystallized ligand (PDB ID: 3IMX, black sticks) in the allosteric site of GK protein

Fig. 3 Docked poses showing H-bond interactions for compound **5b**, **5f**, **5i**, **6c**, **6e** and **6h** in the allosteric binding site of GK protein

and backbone carbonyl of Arg63 residue on GK protein with H-bond distance of 2.9 Å and 2.8 Å respectively. Compound **5i** showed the H-bond interaction between the '1-N' of pyrimidin-2-yl and benzamide NH with NH

and backbone carbonyl of Arg63 residue on GK protein with H-bond distance of 2.9 Å and 2.8 Å respectively. Compound **6c** showed the H-bond interaction between the '3-N' of thiazol-2-yl and benzamide NH with NH

and backbone carbonyl of Arg63 residue on GK protein with H-bond distance of 2.9 Å and 2.9 Å respectively. Compound **6e** showed the H-bond interaction between the '3-N' of thiazol-2-yl and benzamide NH with NH and backbone carbonyl of Arg63 residue on GK protein with H-bond distance of 2.9 Å and 2.9 Å respectively. Compound **6h** showed the H-bond interaction between the '3-N' of thiazol-2-yl and benzamide NH with NH and backbone carbonyl of Arg63 residue on GK protein with H-bond distance of 3.0 Å and 2.9 Å respectively. The molecular docking of the designed 3,5-disubstituted benzamide derivatives in the allosteric site of GK protein helped in understanding the mechanism of GK activation by these newly designed molecules and also helped in predicting that the designed 3,5-disubstituted benzamide derivatives could act as potent allosteric activators of GK enzyme.

In vivo antihyperglycemic activity

Based on screening by in vitro GK assay and in silico docking studies selected compounds (**5b**, **5f**, **5i**, **6c**, **6e** and **6h**) were further evaluated for their glucose lowering effect in animal models by means of OGTT assay. The results of antihyperglycemic activity (i.e., OGTT assay) were measured as blood glucose levels (mg/dL) at different time intervals (0, 30, 60, 90 and 120 min after oral glucose administration) and glucose AUC represented in Figs. 4 and 5, respectively. The results of

Fig. 5 Glucose AUC reduction exhibited by the selected compounds (**5b**, **5f**, **5i**, **6c**, **6e** and **6h**) in rat OGTT model. Ct = control and St = standard. All the values are mean of six measurements ± SD. *Data were significantly different from that of control group (p < 0.05), **Data were not significantly different from that of control group as analyzed statistically by one-way ANOVA

antihyperglycemic activity assay depicted that amongst compounds evaluated in OGTT assay, compounds **6c** and **6e** were found to be highly active with compound **6e** showing better potency than compounds **6c** in OGTT assay. Compound **6e** was almost equipotent to standard antidiabetic drug metformin at 30 and 60 min and decreased the blood glucose levels equivalent to that of standard antidiabetic drug metformin at 120 min

Fig. 4 Effect of selected compounds (**5b**, **5f**, **5i**, **6c**, **6e** and **6h**) on blood glucose levels at specified time intervals in OGTT. Ct = control and St = standard. All the values are mean of six measurements ± SD. The antihyperglycemic activity data of metformin treated group and test groups were significantly different from the control group (p < 0.05); and data of all the groups was also significantly different in various time intervals compared to 0 min interval (p < 0.05)

interval. Compound **6e** was found to reduce significantly glucose AUC compared to control and analogous to that of standard antidiabetic drug. Compounds **5f** and **6h** displayed appreciable reduction in blood glucose levels compared to that of standard drug (metformin) in OGTT assay and these compounds significantly reduced glucose AUC compared to control group. The results of in vivo antihyperglycemic activity assay indicated that the compounds **6c**, **6e** and **6h** followed the similar pattern in blood glucose lowering as that of the standard antidiabetic drug metformin. Compound **5b** was found to be fairly effective in the in vivo antihyperglycemic activity assay compared to standard antidiabetic drug metformin at 120 min interval. Compound **5i** was least effective in reducing blood glucose level in OGTT assay compared to standard drug (St) and reduction in glucose AUC compared to control group (Ct) was not significant. All the compounds tested for antihyperglycemic activity reduced blood glucose in safe range at time interval of 120 min during OGTT assay (i.e., no hypoglycaemic effect was observed during assay period). The control group (vehicle i.e., DMSO only) didn't produce any significant effect on blood glucose levels as well as blood glucose AUC in the OGTT assay.

The results of antihyperglycemic activity assay indicated that substitution with electron withdrawing groups like chloro and nitro at phenyl ring attached to sulphonamide led to increased antidiabetic activity which can be seen from the OGTT assay results of compounds **6c** and **6e**. These antihyperglycemic activity results were in accordance with the results obtained in case of acrylamide derivatives for reduction of blood glucose levels reported by Sidduri et al. [36]. Further the results of antihyperglycemic activity assay indicated that substitution of substituted phenyl ring at sulphonamide nitrogen with alkyl groups like ethyl led to decreased antidiabetic activity which can be seen in case of compound **5i**. Substitution of ethyl group at sulphonamide NH with benzyl group resulted in increased antihyperglycemic activity. The replacement of pyrimidine-2-yl ring (6-membered ring) with thiazol-2-yl ring (5-membered ring) resulted in an increased antihyperglycemic activity which can be seen from the OGTT assay results of compounds **6c** and **6e** compared to that of compounds **5b**, **5f** and **5i**. These antihyperglycemic activity results were supported by a similar study on substituted benzamide derivatives reported as GK activators by Iino et al. [46].

Conclusion

A novel series of 3,5-disubstituted benzamide derivatives were designed and synthesized based on the pharmacophoric features required for binding of allosteric GK activators with GK protein and previously reported 3,5-disubstituted benzamide GK. Amongst the several synthesized derivatives, compounds **5b**, **5f**, **5i**, **6c**, **6e** and **6h** displayed appreciable GK activation profile in the in vitro enzymatic assay. In the docking studies, almost all the synthesized compounds displayed appreciable binding interaction with Arg63 of allosteric site of GK protein. Amongst the compounds tested in vivo for their antihyperglycemic activity (OGTT assay), compounds **6c** and **6e** showed highest antihyperglycemic activity. The results of the in vivo antihyperglycemic activity studies were in parallel to that of the in vitro enzyme assay and in silico docking studies. The molecular properties of these newer benzamide derivatives were also found to follow the Lipinski's rule of five for drug-like property. These newly discovered molecules can serve as the starting hits for the development of safe, potent and orally active GK activators for the treatment of T2D.

Author details
[1] Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India. [2] I. K. Gujral Punjab Technical University, Jalandhar, Punjab 144601, India. [3] Amity Institute of Pharmacy, Amity University, Noida, U.P 201303, India. [4] Shivalik College of Pharmacy, Naya-Nangal, Punjab 140126, India. [5] Jan Nayak Ch. Devi Lal Memorial College of Pharmacy, Sirsa, Haryana 125055, India.

Publisher's Note

Grewal *et al. BMC Chemistry* (2019) 13:2

Page 13 of 14

References

1. Bastaki S (2005) Diabetes mellitus and its treatment. Int J Diabetes Metab 13:111–134
2. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820
3. Cade WT (2008) Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther 88:1322–1335
4. Grewal AS, Bhardwaj S, Pandita D, Lather V, Sekhon BS (2016) Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases. Mini Rev Med Chem 16(2):120–162
5. Skibba M, Hye Khan MA, Kolb LL, Yeboah MM, Falck JR, Amaradhi R et al (2017) Epoxyeicosatrienoic acid analog decreases renal fibrosis by reducing epithelial-to-mesenchymal transition. Front Pharmacol 8:406
6. Kohei K (2010) Pathophysiology of type 2 diabetes and its treatment policy. Japan Med Assoc J 53:41–46
7. Olokoba AB, Obateru OA, Olokoba LB (2012) Type 2 diabetes mellitus: a review of current trends. Oman Med J 27:269–273
8. Pal M (2009) Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug Discov Today 14:784–792
9. Pal M (2009) Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes. Curr Med Chem 16(29):3858–3874
10. Grewal AS, Sekhon BS, Lather V (2014) Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus. Mini Rev Med Chem 14(7):585–602
11. Matschinsky FM, Porte D (2010) Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. F1000 Med Rep 2:43
12. Coghlan M, Leighton B (2008) Glucokinase activators in diabetes management. Expert Opin Investig Drugs 17(2):145–167
13. Perseghin G (2010) Exploring the in vivo mechanisms of action of glucokinase activators in type 2 diabetes. J Clin Endocrinol Metab 95(11):4871–4873
14. Matschinsky FM, Zelent B, Doliba N, Li C, Vanderkooi JM, Naji A et al (2011) Glucokinase activators for diabetes therapy. Diabetes Care 34(Suppl 2):236–243
15. Iino T, Hashimoto N, Hasegawa T, Chiba M, Eiki J, Nishimura T (2010) Metabolic activation of N-thiazol-2-yl benzamide as glucokinase activators: impacts of glutathione trapping on covalent binding. Bioorg Med Chem Lett 20(5):1619–1622
16. Pike KG, Allen JV, Caulkett PW, Clarke DS, Donald CS, Fenwick ML et al (2011) Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life. Bioorg Med Chem Lett 21:3467–3470
17. Li YQ, Zhang YL, Hu SQ, Wang YL, Song HR, Feng ZQ et al (2011) Design, synthesis and biological evaluation of novel glucokinase activators. Chin Chem Lett 22(1):73–76
18. Mao W, Ning M, Liu Z, Zhu Q, Leng Y, Zhang A (2012) Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators. Bioorg Med Chem 20(9):2982–2991
19. Zhang L, Chen X, Liu J, Zhu Q, Leng Y, Luo X et al (2012) Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase. Eur J Med Chem 58:624–639
20. Park K, Lee BM, Kim YH, Han T, Yi W, Lee DH et al (2013) Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus. Bioorg Med Chem Lett 23(2):537–542
21. Park K, Lee M, Hyun H, Lee H, Choi H, Kim H et al (2014) Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus. Bioorg Med Chem 22(7):2280–2293
22. Park K, Lee BM, Hyun KH, Han T, Lee DH, Choi HH (2015) Design and synthesis of acetylenyl benzamide derivatives as novel glucokinase activators for the treatment of T2DM. ACS Med Chem Lett 6(3):296–301
23. Taha MO, Habash M, Hatmal MM, Abdelazeem AH, Qandil A (2015) Ligand-based modeling followed by in vitro bioassay yielded new potent glucokinase activators. J Mol Graph Model 56:91–102
24. Singh R, Lather V, Pandita D, Vikramjeet J, Karthikeyan AN, Singh AS (2016) Synthesis, docking and antidiabetic activity of some newer benzamide derivatives as potential glucokinase activators. Lett Drug Des Discov 14(5):540–553
25. Wang Z, Shi X, Zhang H, Yu L, Cheng Y, Zhang H et al (2017) Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: design, synthesis, and biological evaluation. Eur J Med Chem 139:128–152
26. Charaya N, Pandita D, Grewal AS, Lather V (2018) Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators. Comput Biol Chem 73:221–229
27. Reddy MD, Blanton AN, Watkins EB (2017) Palladium-catalyzed, N-(2-aminophenyl)acetamide-assisted ortho-arylation of substituted benzamides: application to the synthesis of Urolithins B, M6, and M7. J Org Chem 82(10):5080–5095
28. Reddy MD, Uredi D, Watkins EB (2018) A general method for the metal-free, regioselective, remote C–H halogenation of 8-substituted quinolines. Chem Sci 9:1782–1788
29. Reddy MD, Fronczek FR, Watkins EB (2016) Rh-catalyzed, regioselective, C-H bond functionalization: access to quinoline-branched amines and dimers. Org Lett 18(21):5620–5623
30. Mitsuya M, Kamata K, Bamba M, Watanabe H, Sasaki Y, Sasaki K et al (2009) Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators. Bioorg Med Chem Lett 19(10):2718–2721
31. Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, Pettersen J et al (2012) Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem 55(3):1318–1333
32. Cheruvallath ZS, Gwaltney SL, Sabat M, Tang M, Feng J, Wang H et al (2013) Design, synthesis and SAR of novel glucokinase activators. Bioorg Med Chem Lett 23(7):2166–2171
33. Li F, Zhu Q, Zhang Y, Feng Y, Leng Y, Zhang A (2010) Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazole-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl) propanamides as glucokinase activators. Bioorg Med Chem 18(11):3875–3884
34. Pfefferkorn JA, Tu M, Filipski KJ, Guzman-Perez A, Bian J, Aspnes GE et al (2012) The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus. Bioorg Med Chem Lett 22(23):7100–7105
35. Ye N, Xu X, Li F, Ning M, Liu Z, Cao Y et al (2012) Investigation on the oxidation of aryl oxiranylmethanols and the synthesis of 2-aryl-N-thiazolyl-oxirane-2-carboxamides as glucokinase activators. Tetrahedron Lett 53(35):4738–4742
36. Sidduri A, Grimsby JS, Corbett WL, Sarabu R, Grippo JF, Lou J et al (2010) 2,3-Disubstituted acrylamides as potent glucokinase activators. Bioorg Med Chem Lett 20(19):5673–5676
37. Ishikawa M, Nonoshita K, Ogino Y, Nagae Y, Tsukahara D, Hosaka H et al (2009) Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators. Bioorg Med Chem Lett 19(15):4450–4454
38. Takahashi K, Hashimoto N, Nakama C, Kamata K, Sasaki K, Yoshimoto R et al (2009) The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators. Bioorg Med Chem Lett 17(19):7042–7051
39. Iino T, Sasaki Y, Bamba M, Mitsuya M, Ohno A, Kamata K et al (2009) Discovery and structure-activity relationships of a novel class of quinazoline glucokinase activators. Bioorg Med Chem Lett 19(19):5531–5538
40. Hinklin RJ, Boyd SA, Chicarelli MJ, Condroski KR, DeWolf WE, Lee PA et al (2013) Identification of a new class of glucokinase activators through structure-based design. J Med Chem 56(19):7669–7678
41. Filipski KJ, Guzman-Perez A, Bian J, Perreault C, Aspnes GE, Didiuk MT et al (2013) Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif. Bioorg Med Chem Lett 23:4571–4578
42. Zhang L, Tian K, Li Y, Lei L, Qin A, Zhang L et al (2012) Novel phenyl-urea derivatives as dual-target ligands that can activate both GK and PPARγ. Acta Pharmaceutica Sinica B 2(6):588–597
43. Li Y, Tian K, Qin A, Zhang L, Huo L, Lei L et al (2014) Discovery of novel urea derivatives as dual-target hypoglycemic agents that activate glucokinase and PPARγ. Eur J Med Chem 76:182–192
44. McKerrecher D, Allen JV, Bowker SS, Boyd S, Caulkett PW, Currie GS et al (2005) Discovery, synthesis and biological evaluation of novel glucokinase activators. Bioorg Med Chem Lett 15(8):2103–2106
45. McKerrecher D, Allen JV, Caulkett PW, Donald CS, Fenwick ML, Grange E et al (2006) Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. Bioorg Med Chem Lett 16(10):2705–2709

Grewal *et al. BMC Chemistry*   (2019) 13:2

Page 14 of 14

46. Iino T, Tsukahara D, Kamata K, Sasaki K, Ohyama S, Hosaka H et al (2009) Discovery of potent and orally active 3-alkoxy-5-phenoxy-*N*-thiazolyl benzamides as novel allosteric glucokinase activators. Bioorg Med Chem 17(7):2733–2743

47. Iino T, Hashimoto N, Sasaki K, Ohyama S, Yoshimoto R, Hosaka H et al (2009) Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy. Bioorg Med Chem 17(11):3800–3809

48. Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, Nishimura T et al (2011) Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol 80(6):1156–1165

49. Park K (2012) Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus. Arch Pharm Res. 35(12):2029–2033

50. Jain N, Pathak AK, Mundada AB (2012) 3D QSAR study of novel potent benzamide derivatives as glucokinase activator for antidiabetic activity. J Pharm Res 5(8):4045–4047

51. Ericsson H, Sjoberg F, Heijer M, Dorani H, Johansson P, Wollbratt M et al (2012) The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food. Diabetes Res Clin Pract 98:436–444

52. Grewal AS, Lather V, Pandita D, Bhayana G (2017) Synthesis, docking and biological evaluation of phenylacetic acid and trifluoromethylphenyl substituted benzamide derivatives as potential PPARδ agonists. Lett Drug Des Discov 14(11):1239–1251

53. Mookhtiar KA, Kalinowski SS, Brown KS, Tsay YH, Smith-Monroy C, Robinson GW (1996) Heterologous expression and characterization of rat liver glucokinase regulatory protein. Diabetes 45:1670–1677

54. Efanov AM, Barrett DG, Brenner MB, Briggs SL, Delaunois A, Durbin JD et al (2005) A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 146:3696–3701

55. Futamura M, Hosaka H, Kadotani A, Shimazaki H, Sasaki K, Ohyama S et al (2006) An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem 281:37668–37674

56. Banks JL, Beard HS, Cao Y, Cho AE, Damm W, Farid R et al (2005) Integrated modeling program, applied chemical theory (IMPACT). J Comput Chem 26:1752–1780

57. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177–6196

58. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749

59. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750–1759

60. Ahmed MF, Kazim SM, Ghori SS, Mehjabeen SS, Ahmed SR, Ali SM et al (2010) Antidiabetic activity of Vincarosea extracts in alloxan-induced diabetic rats. Int J Endocrinol 2010:841090

61. Liu S, Ammirati MJ, Song X, Knafels JD, Zhang J, Greasley SE et al (2012) Insights into mechanism of glucokinase activation: observation of multiple distinct protein conformations. J Biol Chem 287(17):13598–13610